Fushine(SZ:300497) Xin Lang Zheng Quan·2025-09-29 01:17Core Viewpoint - Fujian Pharmaceutical experienced a slight decline of 0.20% on September 26, with a trading volume of 124 million yuan, indicating a high level of market activity and investor interest [1] Financing Summary - On September 26, Fujian Pharmaceutical had a financing buy-in amount of 20.42 million yuan and a financing repayment of 11.29 million yuan, resulting in a net financing buy-in of 9.13 million yuan [1] - The total financing and securities balance for Fujian Pharmaceutical reached 420 million yuan, accounting for 7.71% of its circulating market value, which is above the 80th percentile level over the past year, indicating a high financing level [1] - The company had a securities lending repayment of 300 shares on the same day, with no shares sold, and a securities lending balance of 16.19 million yuan, also above the 90th percentile level over the past year [1] Business Performance - As of June 30, Fujian Pharmaceutical reported a total of 22,400 shareholders, a decrease of 2.90% from the previous period, while the average circulating shares per person increased by 2.99% to 20,216 shares [2] - For the first half of 2025, the company achieved an operating income of 515 million yuan, a year-on-year decrease of 24.58%, while the net profit attributable to the parent company was -6.91 million yuan, reflecting a year-on-year increase of 69.23% [2] Dividend and Shareholding Information - Since its A-share listing, Fujian Pharmaceutical has distributed a total of 359 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, among the top ten circulating shareholders, the "Zhejiang Medical Health Industry Stock" ranked as the fifth largest shareholder with 5.24 million shares, an increase of 493,600 shares from the previous period [3] - "Zhejiang Quality Growth Mixed A" entered as the ninth largest shareholder with 3.61 million shares, marking a new investment [3]